Disclaimer and forward-looking statements

Forward looking statements

This communication including the accompanying oral presentation contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers” and words of similar import or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Company’s products by the market in case they obtained regulatory approval, competition from other biotechnology, chemical and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, early stage of sales and marketing structure and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.
Basilea — At a glance

- Revenue-generating, commercial-stage Swiss biotech company with solid cash position (YE2018 ~CHF 223mn)
- Focused in the areas of oncology, hospital antibiotics and hospital antifungals
- Two marketed anti-infective brands (Cresemba and Zevtera) and three oncology drug candidates in development
- Potential for sustainable growth and value generation based on increasing revenues and selective investments into internal and external innovation
- Founded in 2000 as spin-off from Roche
- Listed on the SIX Swiss Stock Exchange since 2004 (SIX: BSLN)
- Based in life sciences hub Basel (Switzerland)
## Potential for sustainable growth and value creation based on commercialized products and innovative pipeline

<table>
<thead>
<tr>
<th>PRODUCTS / INDICATION</th>
<th>PRODUCT CANDIDATES / TARGET POPULATION</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>MARKET</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTIFUNGALS</strong></td>
<td><strong>Cresembra® (isavuconazole)</strong></td>
<td>i.v. and oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Invasive aspergillosis and mucormycosis (U.S. and EU and several other countries)</td>
<td>i.v. and oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Invasive fungal infections (Japan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANTIBIOTICS</strong></td>
<td><strong>Zevteria®/Mabelio® (ceftobiprole)</strong></td>
<td>i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital- and community-acquired pneumonia (HAP, CAP) (major European and several non-European countries)</td>
<td>i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute bacterial skin and skin structure infections (ABSSSI)</td>
<td>i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Staphylococcus aureus (MSSA / MRSA) bacteremia (bloodstream infections)</td>
<td>i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td><strong>Derazantinib (BAL087) panFGFR kinase inhibitor</strong></td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intrahepatic cholangiocarcinoma (ICCA) – registrational study</td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urothelial cancer – monotherapy and combination with atezolizumab (Tecentriq)®</td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>BAL101553 tumor checkpoint controller</strong></td>
<td>48 hr. i.v.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer, glioblastoma</td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glioblastoma (ongoing), solid tumors (completed)</td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glioblastoma – combination with radiotherapy</td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>BAL3833 panRAF/SRC kinase inhibitor</strong></td>
<td>oral</td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Internal &amp; external innovation</strong></td>
<td></td>
<td></td>
<td>Research</td>
<td>Development</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Established strong partnerships to fully exploit commercial potential of Cresemba® and Zevtera®

License partners

- **Pfizer**, for Europe (ex. Nordics), China, Asia-Pacific, Russia, Turkey and Israel (Cresemba)
- **Astellas**, for the U.S. (Cresemba)
- **Asahi Kasei Pharma**, for Japan (Cresemba)
- **CR Gosun**, for China (Zevtera)

Distribution partners

- **Correvio**, for Europe (ex. Nordics), Israel (Zevtera)
- **Hikma**, for MENA region (Cresemba and Zevtera)
- **Grupo Biotoscana**, for LatAm (Cresemba and Zevtera)
- **Unimedic**, for Nordics (Cresemba and Zevtera)
- **Avir**, for Canada (Cresemba and Zevtera)
>100 countries covered by partnerships — USD 1.1bn in total potential milestones

Ongoing participation

- Double-digit royalties on sales by license partners
- Participation through transfer price structure in sales by distribution partners
- Approximately USD 245mn upfront and milestone payments received; USD 1.1bn in potential milestones remaining
**Antifungal**

**Cresemba®**
*(isavuconazole)*

- Invasive mold infections
- Marketed in North America, Europe and Latin America
Invasive fungal infections — An area of continued high unmet medical need

• Severe, potentially life-threatening infections mainly affecting immunocompromised patients

• An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens

• Rising number of immunocompromised patients (cancer and transplantations) driving therapeutic demand

• Mucorales infections on the rise – doubled from 2000 to 2013

• Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents

Mortality rates for invasive fungal infections**

- **CANDIDA**
  - 23 – 40%

- **ASPERGILLUS**
  - 34 – 58%

- **MUCORALES**
  - 40 – 80%

Cresemba continues strong sales uptake in established and new markets

Approx. USD 170mn in-market sales in MAT Q1 2019

LDC: USD corrected for currency fluctuations; MAT: Moving annual total; Source: IQVIA, March 2019
Sales of best-in-class antifungals* by product

USD 3bn sales (MATQ4 2018)

- **VFEND** (VORICONAZOLE) 23% (USD 698 mn)
- **POSACONAZOLE** 25% (USD 747 mn)
- **CASPOFUNGIN** 16% (USD 467 mn)
- **MICAFUNGIN** 11% (USD 343 mn)
- **ANIDULAFUNGIN** 6% (USD 171 mn)
- **ISAVUCONAZOLE** 5% (USD 159 mn)
- **AMBISOME** 14% (USD 436 mn)

VFEND (VORICONAZOLE) 2014 worldwide peak sales approx. USD 900 mn

*Best-in-class antifungals: isavuconazole, posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, December 2018
Cresemba — Differentiated by spectrum, safety and tolerability

- Broad spectrum of activity against molds, including emerging molds (mucorales)
- Consistent plasma levels
- Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study
- Can be administered in patients with renal impairment
- Manageable drug-drug interaction profile
- Once daily maintenance dose, i.v./oral treatment

- ECIL-6 guideline: Cresemba recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile.

ECIL: The European Conference on Infections in Leukaemia
Cresemba — Marketed in North America, Europe, Latin America and further country launches planned

- Marketed in major European countries by Pfizer
  - USD 5mn sales milestone triggered in Q1 2019
- Marketed in the U.S. by Astellas
  - Astellas reported FY18 (ended 03/19) sales of USD 119mn (+37% Y-o-Y)
  - CHF 10mn sales milestone triggered in Q4 2018
- Anticipated to double the number of launched countries by end-2019
- Exclusivity through 2027 in the U.S. and potential pediatric exclusivity extension to 2027 (from 2025) in the EU

Approved in Europe for the treatment of adults with:
invasive aspergillosis and mucormycosis for whom amphotericin B is inappropriate

Approved in the U.S. for the treatment of adults with:
invasive aspergillosis and invasive mucormycosis

For full U.S. prescribing information see: www.cresemba.com
Ceftobiprole is not approved in the U.S.

**Antibacterial**

**Zevtera®/Mabelio®**
**(ceftobiprole)**

- Hospital* and community-acquired pneumonia
- Marketed in major European countries, Argentina, Canada, Peru, and Saudi-Arabia

* HAP (excluding VAP)
Zevtera/Mabelio — A fast-acting hospital antibiotic with activity against a broad range of bacteria

- Broad-spectrum anti-MRSA cephalosporin (including Gram-negative bacteria)
- Rapid bactericidal activity
- Potential to replace antibiotic combinations
- Early improvement in HAP, particularly in patients with MRSA, and CAP, including high-risk patients
- Cephalosporin class safety profile
- Marketed in major European markets, Argentina, Canada, Peru and Saudi Arabia

Approved in major European countries & several non-European countries for both hospital-acquired pneumonia (HAP), excluding ventilator-acquired pneumonia (VAP), and community-acquired pneumonia (CAP)

Not approved in the U.S.
Anti-MRSA hospital antibiotics market — A USD 3.1bn market with the U.S. being the most important region

Global anti-MRSA hospital antibiotics sales*  
USD 3.1bn (MAT Q4 2018)

- USA 47%  
- CHINA 14%  
- JAPAN 4%  
- EU top 5 19%  
- ROW 16%

Linezolid sales by region 2014 (before LOE)
- USA 64%  
- EU 5 7%  
- Japan 6%  
- ROW 6%

Daptomycin sales by region 2015 (before LOE)
- USA 89%  
- EU 5 3%  
- Japan 2%  
- ROW 6%

* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, oritavancin and tedizolid

MRSA: Methicillin-resistant Staphylococcus aureus; LOE: Loss of exclusivity; ROW: Rest of world  
MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, December 2018
Ceftobiprole — Strategy for accessing the important U.S. market providing attractive risk-return profile

- U.S. registration requires two cross-supportive phase 3 studies
  - FDA has approved Special Protocol Assessments for ABSSSI and SAB phase 3 studies
  - ABSSSI and SAB studies ongoing
- Few approved SAB agents available, with limitations, mainly related to resistance or tolerability
- For SAB, ceftobiprole has potential to be positioned as a rapidly cidal agent against both MSSA and MRSA with the favourable safety profile of a cephalosporin
- BARDA funding of up to USD 128mn (~70% of the total estimated program costs) to support U.S. phase 3 program*
- QIDP designation (SAB, ABSSSI, CABP): exclusivity extended to 10 years upon approval

*SAB: Staphylococcus aureus bacteremia; ABSSSI: acute bacterial skin and skin structure infection; CABP: community-acquired bacterial pneumonia

*The project is funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under Contract No. HHS0100201600002C
Oncology

Derazantinib (BAL087)

panFGFR kinase inhibitor for various solid tumors
Derazantinib — targeting FGFR-driven tumors as single agent and in combination with immunotherapy

- Small molecule, oral inhibitor of Fibroblast Growth Factor Receptor (FGFR) family of kinases in-licensed from ArQule Inc.
  - panFGFR kinase inhibitor with strongest activity against FGFR1, 2 and 3
  - Exploring therapeutic potential of additional targets of derazantinib, including targets not addressed by other selective FGFR inhibitors, such as CSF1R (Colony-stimulating Factor 1 Receptor) kinase

- Strong data foundation generated to support potential accelerated FDA approval in intrahepatic cholangiocarcinoma (iCCA), an indication with high unmet need and globally increasing incidence

- Orphan drug designation in iCCA granted by FDA and EMA

- Collaboration with Roche to study derazantinib and immune-checkpoint inhibitor atezolizumab (Tecentriq®) in a clinical study in urothelial cancer

18 Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution
Derazantinib — Significant potential beyond iCCA and urothelial cancer

Frequency of FGFR aberrations across different tumor types

- Glioma ~8%
- Head and neck ~5%
- Non-small cell lung ~5%
- Breast ~17%
- Gastric ~7%
- iCCA ~13-22%
- Renal cell ~5%
- Pancreatic ~5%
- Colorectal ~4%
- Ovarian ~9%
- Endometrial ~11%
- Urothelial ~32%
- Sarcoma ~4%

Source:
Helsten et al., Clin Cancer Res 2016 (22), 257-267;
FGFR2 fusions in iCCA: Graham et al. Hum Pathol 2014 (45), 1630-1638;
Jain et al. J CO Precis Oncol 2018 (2) 1-12
Derazantinib — Established proof-of-concept in iCCA in phase 1/2a study

- Subgroup analysis of 29 patients with FGFR2-fusion positive iCCA:
  - Objective response rate of 21%
  - In 72% of patients, tumor response or disease stabilization for ≥16 weeks was achieved*
  - Manageable safety profile

Derazantinib — Time on treatment supports clinical benefit in FGFR2-fusion positive iCCA

Intrapatient comparison of time on study with derazantinib compared to pre-study second-line chemotherapy

Source: Mazzaferro et al. British Journal of Cancer 2018
Derazantinib — potential for accelerated approval with solid clinical data in iCCA

Favorable clinical data from completed phase 1/2 study

• Promising anti-tumor efficacy and clinical safety shown in biomarker-driven clinical study in patients with FGFR2-gene-fusion expressing iCCA

• Derazantinib efficacy compares favorably to standard-of-care (SoC) chemotherapy (cross-trial comparison)
  ◦ Objective Response Rate (ORR) 21% for derazantinib\(^1\) versus <10% for SoC\(^2,3\)
  ◦ Progression-Free Survival (PFS) approx. 6 months\(^1\) versus 3 months for SoC\(^2,3\)

• Manageable safety profile and low discontinuation rate\(^1,4\)

Registriational phase 2 study, ongoing

• Patients with FGFR2-gene-fusion expressing iCCA (2nd-line)

• Encouraging interim results reported early 2019, consistent with the earlier phase 1/2 data

• 21% ORR with six confirmed partial responses from 29 evaluable patients, 83% disease control rate

• Safety profile and tolerability of continuous dosing schedule confirmed

• Final data to be presented mid-2020

Sources:
1  V. Mazzaferro et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer 2018
**FGFR-inhibitors show differences in safety profiles**

<table>
<thead>
<tr>
<th></th>
<th><strong>DZB</strong>&lt;sup&gt;1&lt;/sup&gt; (N=29)</th>
<th><strong>INF</strong>&lt;sup&gt;2&lt;/sup&gt; (N=71)</th>
<th><strong>FUT</strong>&lt;sup&gt;3&lt;/sup&gt; (N=45)</th>
<th><strong>PEM</strong>&lt;sup&gt;4&lt;/sup&gt; (N=89)</th>
<th><strong>Urothelial cancer</strong>&lt;sup&gt;5&lt;/sup&gt; (N=108)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosing regimen</strong></td>
<td>300mg QD</td>
<td>125mg Q4W QD for 3w</td>
<td>16 mg, 20 mg or 24 mg QD</td>
<td>13.5mg Q3W QD for 2w</td>
<td>13.5mg Q3W QD for 2w</td>
</tr>
</tbody>
</table>
| **Most frequent AEs** | Phosphorus↑
Dry mouth
Nausea | Phosphorus↑
Fatigue
Stomatitis | Phosphorus↑
Constipation
AST↑ | Phosphorus↑
Alopecia
Diarhoea | Diarhoea
Alopecia
Constipation |
| **Blood phosphorus↑†** | 76%                         | 73%                      | 80%                      | 61%                      | 31%                             |
| **Fatigue↑ [G 3]**  | 41% [3%]                    | 49% [4%]                 | NR                      | 36% [4%]                 | 32% [6%]                        |
| **Alopecia↑**      | 28%                         | 38%                      | NR                      | 37%                      | NR                              |
| **Dry eye/xerophthalmia↑** | 21%                         | 32%                      | NR                      | 20%                      | NR                              |
| **Central serous retinopathy** | 0%                          | NR                      | NR                      | NR                      | NR                              |
| **ALT↑**           | 31%                         | NR                      | 31%                     | NR                      | 41%[7]                          |
| **Hand-foot syndrome/PPE** | 0%                          | 27%                     | 22%                     | NR                      | ≥22%                            |
| **Nail events (drug-related)** | <5%                         | NR                      | NR                      | NR                      | 52%                             |
| **Stomatitis**     | 7%                          | 45%                      | 22%                     | 30%                     | 34%                             |

**Sources:**
1 Mazzaferro et al., Br J Cancer 2018 and Basilea data on file; 2 Javle et al., ESMO 2018; 3 Meric-Bernstam et al, ESMO WC GI Cancer, 2018; 4 Hollebecque et al., ESMO 2018; 5 Necchi et al., ESMO 2018; 6 Siefker-Radtke et al., ASCO 2018; 7 Balversa<sup>®</sup> US prescribing information (April 2019) based on reported laboratory abnormalities N=86 patients, regardless of causality.

**Abbreviations:**
DZB: derazantinib, INF: infigratinib (BJ G398), FUT: futibatinib (TAS-120), PEM: pemigatinib (INCB54828), ERD: erdafitinib;
PPES: Palmar-plantar erythrodysesthesia; NR: not reported; QD, daily; Q3W/Q4W, every 3/4 weeks; w, weeks.

*Drug-related events reported only; † assumed FGFR inhibitor class-effect.
FGFR inhibitors show differences in kinase-inhibition profiles

<table>
<thead>
<tr>
<th>FGFR-inhibitor compound (Sponsor)</th>
<th>Parameter</th>
<th>FGFR1</th>
<th>FGFR2</th>
<th>FGFR3</th>
<th>FGFR4</th>
<th>CSF1R (FMS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derazantinib (Basilea)</td>
<td>Ratio to FGFR2 activity</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>77</td>
<td>3</td>
</tr>
<tr>
<td>Pemigatinib (Incyte)</td>
<td>Ratio to FGFR2 activity</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>39</td>
<td>231</td>
</tr>
<tr>
<td>Erdafitinib (Janssen)</td>
<td>Ratio to FGFR2 activity</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>13</td>
<td>95</td>
</tr>
<tr>
<td>Rogaratinib (Bayer)</td>
<td>Ratio to FGFR2 activity</td>
<td>5</td>
<td>1</td>
<td>6</td>
<td>18</td>
<td>116</td>
</tr>
<tr>
<td>Infigratinib (QED)</td>
<td>Ratio to FGFR2 activity</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>47</td>
<td>86</td>
</tr>
<tr>
<td>Futibatinib (Taiho)</td>
<td>Ratio to FGFR2 activity</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>18</td>
<td>NA</td>
</tr>
</tbody>
</table>

Source: Basilea data on file
Potential therapeutic relevance of CSF1R-inhibition

- Derazantinib is active in inhibiting FGFR kinases and CSF1R (Colony-stimulating factor-1 receptor).
- CSF1R inhibition may reprogram immunosuppressive tumor-infiltrating macrophages, restore T-cell activity and thereby improve the susceptibility to PD1/PD-L1 inhibitors.
- Derazantinib may address several oncogenic mechanisms at the same time, i.e. inhibiting FGFR and making the tumor more susceptible to immunotherapy.
- Basilea entered into a collaboration with Roche to study a combination of derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab in patients with urothelial cancer.

Derazantinib/atezolizumab - a potential unique FGFR/IO combination in urothelial cancer

• Among FGFR-inhibitors, CSF1R inhibition seems unique to derazantinib

• In urothelial cancer, Keytruda® and Tecentriq® received label restrictions on the use for first-line treatment of patients with low PD-L1 expression
  ◦ This subgroup of tumors shows frequent FGFR genomic abnormalities (mainly FGFR3 fusions)
  ◦ Derazantinib combined with PD1/PD-L1 inhibitors may therefore provide benefits related to multiple mechanisms (FGFR inhibition, macrophage inhibition, enhanced response to immunotherapy) in this group of patients

• A phase 1/2 study exploring derazantinib as monotherapy and in combination with Tecentriq® anticipated to start mid-2019
Oncology

BAL101553

Treatment-refractory solid tumors, including glioblastoma
BAL101553 — Novel tumor checkpoint controller crossing the blood-brain barrier

- Novel compound inducing tumor cell death through checkpoint activation
- Destabilizing the microtubule scaffold through a novel target-binding site
- Targeting diverse tumor types resistant to standard therapeutic approaches
- Crosses the blood-brain barrier with potent activity in brain tumor models alone and in combination
- Flexible dosing potential, including daily oral dosing
- Comprehensive biomarker program to optimize patient and tumor selection

* BAL101553 is a prodrug of BAL27862

Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution
**BAL101553 — three ongoing clinical studies**

- **Phase 2a expansion (weekly 48-hour i.v.)** in patients with recurrent glioblastoma or platinum-resistant ovarian cancer
  - Anticipated to complete around year-end 2019

- **Phase 1 dose escalation (daily oral)** in patients with recurrent glioblastoma
  - Anticipated to complete in mid-2019

- **Phase 1 study (daily oral) in combination with radiotherapy** in patients with newly diagnosed glioblastoma in collaboration with the Adult Brain Tumor Consortium (ABTC)\(^1\)
  - Anticipated to complete patient enrolment mid-2020

---

\(^1\) The ABTC is funded by the U.S. National Cancer Institute (NCI)
Oncology

BA L3833

Treatment-refractory solid tumors, including metastatic melanoma and RAS-driven tumors
In-licensed novel, oral, small molecule drug from consortium around Wellcome Trust & Institute of Cancer Research (ICR)

- Dual-targeting kinase inhibitor
- Targets resistance mechanisms associated with approved BRAF inhibitors (including vemurafenib and dabrafenib)
- Resistance-reversal activity in BRAF/MEK inhibitor- and immunotherapy-resistant melanoma models
- Potential in diverse non-melanoma tumor types:
  - e.g. RAS-driven tumors
  - Expanded biomarker program to aid tumor selection

Phase 1 dose-escalation study completed
  - Broad dose range investigated, maximum tolerated dose (MTD) was not defined
  - Pre-clinical activities ongoing to explore alternative formulations

BAL3833 — panRAF/SRC kinase inhibitor

Cell changes in gene expression
### Key financials 2018 and 2019 guidance

<table>
<thead>
<tr>
<th>In CHF mn</th>
<th>FY 2019 guidance</th>
<th>FY 2018 actuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenue</td>
<td>128 - 138</td>
<td>132.6</td>
</tr>
<tr>
<td>thereof: Contributions from Cressemba &amp; Zevtera</td>
<td>100 - 110</td>
<td>82.0</td>
</tr>
<tr>
<td>Operating loss</td>
<td>20 - 30</td>
<td>24.1</td>
</tr>
<tr>
<td>Net operating cash consumption</td>
<td>55 - 65</td>
<td>79.2</td>
</tr>
<tr>
<td>Year-end cash and financial investments</td>
<td>n/a</td>
<td>223.0</td>
</tr>
</tbody>
</table>

#### Strong increase in Cressemba & Zevtera revenue contributions Y-o-Y, CHF mn

![Bar chart showing revenue contributions from 2015 to 2019 for Cressemba & Zevtera].

32  Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution
## Focus 2019 and beyond

**Cresemba® & Zevtera®/Mabelio®** Increasing cash-generating revenues  
By the end of 2021, Cresemba to be on the market in >60 countries

<table>
<thead>
<tr>
<th>H1 2019</th>
<th>H2 2019</th>
<th>H1 2020</th>
<th>H2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ceftobiprole</strong></td>
<td></td>
<td>Top line results from phase 3 ABSSSI study</td>
<td></td>
</tr>
<tr>
<td><strong>Derazantinib</strong></td>
<td>Interim analysis of phase 2 registrational study in iCCA FGFR2 fusions</td>
<td>Complete patient enrolment in phase 2 registrational study in iCCA</td>
<td>Top line results from phase 2 registrational study in iCCA</td>
</tr>
<tr>
<td></td>
<td>Collaboration with Roche in urothelial cancer</td>
<td>Start phase 2 study in urothelial cancer</td>
<td>Interim data from first cohort(s) in urothelial cancer</td>
</tr>
<tr>
<td></td>
<td>Expand ongoing iCCA study in other FGFR gene aberrations</td>
<td></td>
<td>Interim data from iCCA in other FGFR gene aberrations</td>
</tr>
<tr>
<td><strong>BAL101553</strong></td>
<td>Complete patient enrolment in phase 1 study arm for recurrent glioblastoma (oral)</td>
<td>Top line results from phase 2a study in ovarian cancer and glioblastoma (48-hr. i.v.)</td>
<td>Complete patient enrolment in phase 1 study in newly diagnosed glioblastoma</td>
</tr>
</tbody>
</table>
Appendix
## Basilea leadership

### Management Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Veitch</td>
<td>CEO</td>
</tr>
<tr>
<td>Marc Engelhardt, MD, Ph.D.</td>
<td>CMO</td>
</tr>
<tr>
<td>Dr. Gerrit Hauck, Ph.D.</td>
<td>CTO</td>
</tr>
<tr>
<td>Laurenz Kellenberger, Ph.D.</td>
<td>CSO</td>
</tr>
</tbody>
</table>

**David Veitch** - CEO (2014)
- Bristol-Myers Squibb
- SmithKline Beecham

**Marc Engelhardt**, MD, Ph.D. - CMO (2010)
- Novartis
- Bracco

**Dr. Gerrit Hauck**, Ph.D. - CTO (2018)
- Sanofi

- University of Cambridge
- Roche
Antifungal

Cresemba®
(isavuconazole)

- Invasive mold infections
- Marketed in North America, Europe and Latin America
Significant sales of best-in-class antifungals in all major regions — Covered by our partnerships

USD 3bn sales of best-in-class antifungals* (MATQ4 2018)

* Best-in-class antifungals: isavuconazole, posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, December 2018
Cresemba – strong global roll out

Number of launched countries

- 2015: x1
- 2016: x2
- 2017: x2
- 2018: x2
- 2019: x3
- 2020: x3
- 2021: x3

Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution
Isavuconazole — SECURE phase 3 data (efficacy)

SECURE: Primary treatment of invasive fungal disease caused by Aspergillus spp. and other filamentous fungi

• Met primary objective of non-inferiority vs. voriconazole

All-cause mortality through day 42

<table>
<thead>
<tr>
<th></th>
<th>Isavuconazole n=258</th>
<th>Voriconazole n=258</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18.6%</td>
<td>20.2%</td>
</tr>
</tbody>
</table>

Maertens The Lancet 2016
Isavuconazole — Positive VITAL phase 3 data

Treatment of invasive fungal disease caused by emerging fungi such as Mucorales spp., including patients with pre-existing renal impairment (open-label study, n=149)

- All-cause-mortality through day 42 in renally impaired patients with invasive aspergillosis (n=20) for which i.v. voriconazole can only be used with caution:
  - 15% (vs. 18.6% benchmark in SECURE study, excluding patients with moderate to severe renal impairment)*

- All-cause-mortality through day 42 in patients with confirmed mucormycosis (n=37), including patients refractory or intolerant to other antifungal therapies:
  - 38% (similar to data reported in the literature for amphotericin B)**

* Basilea Pharmaceutica data on file; ** Marty The Lancet Infectious Diseases 2016
Zevtera®/Mabelio® (ceftobiprole)

- Hospital* and community-acquired pneumonia
- Marketed in major European countries, Argentina, Canada, Peru and Saudi Arabia

* HAP (excluding VAP)
Phase 3 study with ceftobiprole in the treatment of patients with ABSSSI

- **Design:** randomized, double-blind, multi-center

- **Enrolment:** approximately 674 adult patients (male and female)

- **Indication:** acute bacterial skin and skin structure infection (ABSSSI)

- **Main inclusion criteria:** diagnosis of ABSSSI, requirement of i.v. treatment

- **Intervention:** ceftobiprole medocaril i.v.; comparator vancomycin i.v. (plus aztreonam to cover Gram-negative bacteria)

- **Primary endpoint:** non-inferiority of ceftobiprole to vancomycin (plus aztreonam) for early clinical response based on percentage reduction in lesion size at 48–72 hours after first treatment

- **Secondary endpoint** (primary for EMA): investigator-assessed clinical success at the test-of-cure (TOC) visit 15–22 days after randomization

Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution
Phase 3 study with ceftobiprole in the treatment of patients with SAB

- **Design:** randomized, double-blind, multi-center

- **Enrolment:** approximately 390 adult patients (male and female)

- **Indications:** Staphylococcus aureus bacteremia (SAB), including endocarditis (IE) and other forms of complicated SAB

- **Main inclusion criteria:** Positive *S. aureus* blood culture and signs & symptoms for SAB

- **Intervention:** ceftobiprole medocaril i.v.; comparator daptomycin i.v. or daptomycin plus aztreonam to cover Gram-negative bacteria

- **Primary endpoint:** non-inferiority of ceftobiprole to daptomycin for overall success as assessed by an independent Data Review Committee (DRC) in the treatment of SAB, including IE, at the post-treatment evaluation (PTE) visit (70 days after randomization) in the modified intent-to-treat (mITT) population.

- **Secondary endpoints:** include all-cause mortality at Day 28 and Day 70 (PTE visit) in the intent-to-treat (ITT) and mITT populations; and time to *S. aureus* bloodstream clearance
MRSA titers in cardiac vegetations (bacterial masses), spleens and kidneys of untreated and antibiotic treated rabbits infected with MRSA strain COL (highly methicillin-resistant)

* Differences in favor of ceftobiprole statistically significant

Tattevin Antimicrob Agents Chemother 2010
Ceftobiprole — Trend towards lower 30-day all-cause-mortality for SAB* patients treated in phase 3 studies

- Pooled analysis from four double-blind, randomized phase 3 studies (2x ABSSSI, HABP, CABP)

**30-day all-cause mortality**

<table>
<thead>
<tr>
<th>Bacteremia due to:</th>
<th>Comparator</th>
<th>Ceftobiprole</th>
<th>Difference (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All staphylococcal species</td>
<td>8/50</td>
<td>4/45</td>
<td>-7.1 (-20.2, 6.0)</td>
</tr>
<tr>
<td>Coagulase-negative staphylococci (CoNS)</td>
<td>2/22</td>
<td>1/22</td>
<td>-4.5 (-19.4, 10.3)</td>
</tr>
<tr>
<td>S. aureus</td>
<td>6/28</td>
<td>3/23</td>
<td>-8.4 (-28.9, 12.1)</td>
</tr>
<tr>
<td>Methicillin-sensitive Staphylococcus aureus (MSSA)</td>
<td>2/15</td>
<td>1/9</td>
<td>-2.2 (-29.0, 24.6)</td>
</tr>
<tr>
<td>Methicillin-resistant Staphylococcus aureus (MRSA)</td>
<td>2/9</td>
<td>0/9</td>
<td>-22.2 (-49.4, 4.9)</td>
</tr>
</tbody>
</table>

Comparators: ABSSSI: vancomycin, vancomycin + ceftazidime / CABP: ceftriaxone ± linezolid / HABP: linezolid + ceftazidime

*Staphylococcus aureus bacteremia*
Oncology

Derazantinib (BAL087)

panFGFR kinase inhibitor for various solid tumors
Design: Multi-national, open-label, non-comparative study

Enrolment: 100 adult patients

Indications: Intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions (2nd-line)

Main inclusion criteria:
- Adult subjects with locally advanced (inoperable) or metastatic iCCA whose tumors harbor FGFR2 gene fusions and who received at least one prior regimen of systemic therapy
- Measurable disease by RECIST 1.1

Intervention: 300 mg oral ARQ 087 once daily

Primary endpoint: Objective Response Rate (ORR)

Secondary endpoints: Progression-free survival (PFS), Overall Survival (OS), Duration of response (DoR), Safety
Derazantinib — Significant potential beyond iCCA

Frequency of currently known FGFR aberrations across tumor types
